| Summary: | Background: The rate of metabolic syndrome in the patients with schizophrenia
receiving atypical antipsychotic therapy was higher than in those receiving typical
antipsychotics. The antipsychotic polypharmacy is also considered to cause the
increased the rate of metabolic syndrome. The metabolic syndrome in the patients
with schizophrenia will lead to an increase in mortality due to development of a
premature cardiovascular disease.
Objective: To determine differences in the frequency of metabolic syndrome in
the patients with schizophrenia who were given combination therapy of haloperidol
and clozapine compared with haloperidol monotherapy.
Methods: Cross-sectional study was conducted in Yogyakarta on 64 outpatients
with schizophrenia of Grhasia Hospital. The patients were divided into 2 groups,
i.e. group of monotherapy and combination therapy. The Chi-Square test was used
to analyze the correlation of the metabolic syndrome with gender, age, education,
employment status, type of therapy, dose of therapy, duration of therapy, smoking
habit, diet, and physical activity.The logistic regression analytic was used to
analyze the variables that play roles in the occurrence of the metabolic syndrome.
Result: The frequency of metabolic syndrome in combination therapy group was
lower than the monotherapy group
|
|---|